Trial: 201901190

A Phase 1/2 Study of Oral LOXO-292 in Patients with Advanced Solid Tumors, Including RET Fusion-Positive Solid Tumors, Medullary Thyroid Cancer, and Other Tumors with RET Activation (LIBRETTO-001)



Principal Investigator

Waqar, Saiama

Disease Site

Ill-Defined Sites; Lip, Oral Cavity and Pharynx; Lung; Lung Cancer – Non-small Cell

Learn more about this study at: